Targeted brain stimulation for contamination-based OCD
Official title: Individually Targeted Neuromodulation for Contamination-based Obsessive-compulsive Disorder
Run by Mclean Hospital · NCT05048251 · Data updated 2026-11-12
This study is testing a new brain stimulation treatment to see if it can help people with OCD who struggle with contamination and washing symptoms feel better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Mclean Hospital Academic / other |
| Locations | 1 site (Belmont, Massachusetts) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | June 30, 2024 |
| Study ends | June 30, 2024 |
| Registry record updated | March 15, 2024 |
| Trial ID | NCT05048251 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-55 with a primary diagnosis of OCD and predominant contamination symptoms.
✕Probably not a fit
Patients with OCD who do not primarily experience contamination symptoms or those on certain psychiatric medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates a novel method of transcranial magnetic stimulation (TMS) aimed at reducing contamination and washing symptoms in patients with obsessive-compulsive disorder (OCD). It focuses on the specific brain networks associated with these symptoms, utilizing advanced imaging techniques to identify connectivity patterns. The approach is designed to personalize treatment by targeting the right medial frontal gyrus and its connections to the ventral attention network, which are believed to play a role in the severity of contamination symptoms. The study will involve a two-phase program to assess the effectiveness of this targeted intervention.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatments for patients suffering from contamination-based OCD.
How similar studies have gone: While there have been studies on TMS for OCD, this specific targeted approach is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. male or female age 18-55 years old 2. DSM-5 diagnosis of OCD as primary presenting disorder 3. CONTAM as the predominant symptom dimension (i.e., Dimension 4 (CONTAM symptoms) is the highest score on the Dimensional Yale-Brown Obsessive Compulsive Scale (D-YBOCS); participants with more than one Dimension as highest score will still be eligible as long as Dimension 4 is one of these) 4. score of ≥ 8 on Dimension 4 of the D-YBOCS 5. taking no psychiatric medications or on a stable dose of an SSRI, clomipramine, SNRI, or second generation antipsychotic for at least 4 weeks prior to enrollment. Use of PRN benzodiazepines will be permitted as long as the dose/usage has not changed significantly leading up to enrollment. No medication changes will be permitted during the study 6. have not initiated a new course of exposure and response prevention (ERP) therapy within 4 weeks of enrollment (ongoing ERP will be permitted if initiated more than 8 weeks before enrollment). Exclusion Criteria: 1. positive urine drug screen (other than prescribed benzodiazepines) 2. use of psychiatric medications other than permitted above 3. substance use disorder in the last 3 months (with the exception of nicotine) 4. history of schizophrenia, bipolar disorder, autism, Tourette's syndrome (current and past history of depressive, anxiety, and eating disorders permitted as long as OCD is considered the primary disorder) 5. active suicidal ideation over the week prior to screening (as indicated by answering yes to questions 1 or 2 on the C-SSRS) 6. history of traumatic brain injury, seizure disorder, neurodegenerative disease, or other organic brain disease 7. pregnancy or lactating 8. contraindication to MRI scanning or TMS
Where it's running
-
McLean Hospital
Belmont, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Brian P Brennan, MD — Mclean Hospital
- Study coordinator: Rosalind Sokoll
- Email: rsokoll@mgh.harvard.edu
- Phone: 617-855-2911
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-intensity focused ultrasound targeting the subthalamic nucleus for OCD
A short test is being done to see if a wearable, non-invasive ultrasound device can safely and tolerably help adults with OCD by targeting a brain region called the subthalamic nucleus.
-
Mindfulness-Based Cognitive Therapy for OCD Delivered Online
This study tests a synchronous online MBCT program for adults with OCD to see if it is acceptable and feasible and to explore links between biological markers, OCD severity, and treatment response.
-
Targeted brain stimulation for OCD: test of tTIS on nucleus accumbens
This study tests whether targeted temporal interference stimulation of the nucleus accumbens can help reduce obsessive-compulsive symptoms in adults with OCD, compared with sham stimulation.
-
Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety
This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.
-
AttunE LIFU for OCD: a non-invasive brain stimulation study
This trial tests ATTN201, a wearable ultrasound headband, to see if it helps adults with OCD compared to a sham treatment.
-
Combined ERP and Habit Reversal Therapy for Tourettic OCD
This study tests whether a merged Exposure and Response Prevention and Habit Reversal Therapy helps adults with Tourettic OCD more than either therapy alone or basic psychoeducation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.